SecBot SecBot
8-K ·Filed Jun 5, 2026

QUCY

Quantum Cyber N.V.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001213900-26-065802
8-K material event: Items 1.02
Actionable Insight • Neutral

The termination removes a source of equity financing, which could mean the company is conserving shares or has alternative funding. Monitor for any subsequent capital raises or strategic announcements to gauge the company's financing outlook.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
QUCY ▼ -29.52% at T+60d
NEUTRAL call -29.52% · α vs SPY -32.58% · entry $2.10 → $1.48
Entry = T+0 close
Jun 5, 2026
via day close
T+1d
-2.86%
call -2.86% · α -2.56%
$2.04
settled 5mo ago
T+5d
+0.95%
call +0.95% · α -1.16%
$2.12
settled 5mo ago
T+20d
-31.43%
call -31.43% · α -33.06%
$1.44
settled 4mo ago
T+60d
-29.52%
call -29.52% · α -32.58%
$1.48
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Quantum Cyber N.V. terminated its at-the-market (ATM) issuance sales agreement with Maxim Group LLC, effective June 7, 2026. Prior to termination, the company had sold 3,280,927 ordinary shares under the agreement for net proceeds of approximately $4,388,515. No termination penalties are owed. The termination closes off a source of equity capital, which may signal reduced reliance on dilutive funding or a shift in financing strategy.

Key Facts

  • Terminated ATM sales agreement with Maxim Group LLC effective June 7, 2026.
  • Prior to termination, sold 3,280,927 ordinary shares for net proceeds of approximately $4,388,515.
  • No termination penalties incurred.
  • Agreement originally dated October 1, 2025, and amended on May 4, 2026.

Financial Impact

No further dilution from this ATM facility; approximately $4.4M raised prior to termination. No termination fees or penalties.

dilutioncash

Risk Factors

  • Loss of a flexible equity capital source could constrain liquidity if operating cash flows are insufficient.
  • Potential need for alternative, possibly more expensive, financing in the future.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-065802
Document: 0001213900-26-065802-index-headers.html0001213900-26-065802
Document: 0001213900-26-065802-index.html0001213900-26-065802
Document: 0001213900-26-065802.txt0001213900-26-065802
35 reports for QUCY
Performance horizon
67% Hit rate @ T+20 4 of 6 directional calls Went positive at some point 5 of 7 best @ T+60▲ +39.06%Jun 4, 2026
Filters
Rows
Reports for QUCY — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
Press Release
NEUTRAL ★ 2/10
$1.03awaiting T+20—$0.9051 (−12.13%)
Oct 16, 2026
10d ago
8-K
NEUTRAL ★ 2/10
$1.07awaiting T+20—$0.9051 (−15.41%)
Oct 9, 2026
17d ago
8-K
NEUTRAL ★ 4/10
$1.03awaiting T+20—$0.9051 (−12.13%)
Oct 9, 2026
17d ago
424B5
BEARISH ★ 7/10
$1.03awaiting T+20—$0.9051 (+12.13%)
Sep 28, 2026
29d ago
Press Release
NEUTRAL ★ 3/10
$1.36 $0.8515▼ −37.39%▼ −37.36%$0.9051 (−33.45%)
Sep 25, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$1.37 $1.01▼ −26.28%▼ −24.80%$0.9051 (−33.93%)
Sep 25, 2026
4w ago
Press Release
NEUTRAL ★ 3/10
$1.37 $1.01▼ −26.28%▼ −24.80%$0.9051 (−33.93%)
Aug 13, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$1.42 $1.34▼ −5.63%▼ −3.89%$0.9051 (−36.26%)
Jul 24, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$1.08 $1.30▲ +20.37%▲ +16.74%$0.9051 (−16.19%)
Jul 16, 2026
14w ago
Press Release
NEUTRAL ★ 4/10
$1.19awaiting T+20—$0.9051 (−23.94%)
Showing 10 of 35

US Market Status

Market Closed — Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026